ABIVAX
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Manufacturing
Description
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-01-05 08:00 |
Abivax publie des nouvelles données sur le mécanisme d’action anti-inflammatoir…
|
French | 249.4 KB | ||
| 2023-01-05 08:00 |
Abivax publishes novel data with respect to obefazimods anti-inflammatory mecha…
|
English | 16.7 KB | ||
| 2022-12-21 17:45 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 247.2 KB | ||
| 2022-12-20 18:00 |
Abivax reçoit l’approbation de la FDA pour le plan de développement pédiatrique…
|
French | 207.9 KB | ||
| 2022-12-20 18:00 |
Abivax receives FDA agreement on pediatric development plan with obefazimod in …
|
English | 12.5 KB | ||
| 2022-12-14 18:00 |
Abivax assistera à la 41eme Conférence Annuelle J.P. Morgan Healthcare
|
French | 211.7 KB | ||
| 2022-12-14 18:00 |
Abivax to attend the J.P. Morgan 41st Annual Healthcare Conference
|
English | 12.2 KB | ||
| 2022-11-29 18:00 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 249.6 KB | ||
| 2022-11-15 18:00 |
Abivax annonce les résultats de son Assemblée générale ordinaire et extraordina…
|
French | 153.6 KB | ||
| 2022-11-15 18:00 |
Abivax releases the results of its November 9, 2022 ad hoc ordinary and extraor…
|
English | 7.2 KB | ||
| 2022-10-18 18:00 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 247.8 KB | ||
| 2022-10-11 18:00 |
Abivax inclut le premier patient aux Etats-Unis de son programme global de phas…
|
French | 234.9 KB | ||
| 2022-10-11 18:00 |
Abivax: first US patient enrolled in global phase 3 program with obefazimod in …
|
English | 18.5 KB | ||
| 2022-10-03 18:00 |
ABIVAX ANNONCE LA TENUE D’UNE ASSEMBLEE ORDINAIRE ET EXTRAORDINAIRE AD HOC LE 9…
|
French | 192.1 KB | ||
| 2022-10-03 18:00 |
ABIVAX ANNOUNCES AD HOC ORDINARY AND EXTRAORDINARY GENERAL MEETING ON NOVEMBER …
|
English | 9.7 KB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIVAX
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
Peer Companies
